Kami, as an overall comment, I hope for you, for me and all LTH...

Kami, as an overall comment, I hope for you, for me and all LTH that this management team delivers, the signs so far a good. We're on the doorstep of our first profit in 8 years and that gives me a glimmer of hope that this management team will deliver.

As for your question about ownership of Nexstellis vs just marketing rights, it's a more difficult question to answer. It would obviously be advantageous to have both, but not at any cost.

My personal belief is that we're not in a financial position to acquire those rights. My understanding is that Mithra has structured the future earnings and the intellectual property of Estetrol (native estrogen component in Nextstellis, Donesta and few other canditates ) in a subsiduary company called Estetra and there has been an offer made for Estetra.
I believe that the most likely candidate is Gedeon Richter which already owns marketing rights for Drovelis (Nexstellis in Europe), Donesta and last year also purchased the manufacturing rights for the API (Active Pharmaceutical Ingredient) in Nexstellis and Donesta. My guess is that we're dealing with Gedeon for marketing rights of Donesta in the US should they be the successful purchaser of Estetra.

A consideration in all of this for Mayne Pharma, is the potential liability of US$295M payable to Mithra (or the successful purchaser of Estetra) if cumulative earnings for Nextstellis exceed US$2.25B and also the double digit % of earnings payable each year. I think that cumulative figure is a long way off and may never happen so paying for that potential liability now would not be wise.